UPB · Upstream Bio, Inc.
$6.85
-0.67 (-8.85%)
At close · Aug 20
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Market Cap
$375.18M
Shares
54.77M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.85M
+20.4%
FY2025
Net Income
-$143.44M
-128.4%
FY2025
Operating Margin
-5618.82%
-2337.6pp
FY2025
Diluted EPS
-$2.66
+52.3%
FY2025
Operating Cash Flow
-$133.28M
-125.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $3.16M | $2.85M | $2.37M | $2.38M | |
| $145.8M | $136.81M | $62.97M | $31.8M | |
| $27.34M | $26.41M | $17.17M | $10.7M | |
| — | $188K | $89K | $60K | |
| $173.14M | $163.22M | $80.13M | $42.49M | |
| -$169.98M | -$160.36M | -$77.76M | -$40.11M | |
| — | -5618.82% | -3281.18% | -1685.46% | |
| — | -$160.17M | -$77.68M | -$40.05M | |
| $13.47M | $16.93M | $12.12M | $4.17M | |
| $13.48M | $16.92M | $14.96M | $19.58M | |
| — | $0 | $0 | $0 | |
| -$156.5M | -$143.44M | -$62.81M | -$20.54M | |
| — | -5026.03% | -2650.04% | -862.9% | |
| — | -$143.44M | -$76.4M | -$38.26M | |
| -$156.88M | -$142.89M | -$62.85M | -$20.52M | |
| USD/shares | — | -$2.66 | -$5.58 | -$12.95 |
| USD/shares | — | -$2.66 | -$5.58 | -$12.95 |
| shares | — | 53.85M | 13.68M | 2.95M |
| shares | — | 53.85M | 13.68M | 2.95M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.39×
EV/EBIT
—
Peer median 10.46×
P/E (TTM)
—
Peer median 12.80×
Peer medians compare against the 320 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
2022626
CUSIP
91678A107
13F (30d)
146 filings
144 filers
Visit website
Investor relations